CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Clinical trials for CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for High-Risk melanoma: immunotherapy before and after surgery shows promise
Disease control OngoingThis phase II trial studies whether giving the immunotherapy drug pembrolizumab both before and after surgery is more effective than giving it only after surgery for patients with stage III-IV high-risk melanoma. The study involves 313 participants with detectable melanoma that c…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 01, 2026 15:34 UTC
-
New hope for melanoma patients: could a new drug beat standard care?
Disease control OngoingThis study tests if the drug pembrolizumab works better than the usual treatments (high-dose interferon or ipilimumab) for people with high-risk melanoma that has been removed by surgery. About 1,300 patients took part. The goal is to see if pembrolizumab helps people live longer…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 01, 2026 15:24 UTC
-
Two-Drug combo shows promise against tough cancers
Disease control OngoingThis early-phase trial tests a new combination of two drugs—sonidegib and pembrolizumab—in 36 adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if the combination can shrink tumors. Sonidegib blocks certain enzymes that help cancer gr…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 01, 2026 15:23 UTC
-
New hope for hard-to-treat melanoma? drug combo tested in small trial
Disease control OngoingThis study tests whether adding rigosertib to pembrolizumab can help people with advanced melanoma that no longer responds to standard immunotherapy. The trial enrolled 7 adults with unresectable or metastatic melanoma. Researchers are measuring how many patients' tumors shrink o…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
Which order works best? landmark trial tests immunotherapy vs. targeted therapy for melanoma
Disease control OngoingThis phase III trial tested two different sequences of treatment for people with advanced melanoma that has a BRAF mutation and cannot be removed by surgery. One group started with immunotherapy (ipilimumab + nivolumab) followed by targeted therapy (dabrafenib + trametinib), whil…
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC
-
New drug cocktail shows promise for brain metastases in melanoma patients
Disease control OngoingThis study tests whether combining two or three drugs can shrink or control melanoma that has spread to the brain. It involves 29 adults with untreated brain metastases. The drugs work by blocking tumor growth and helping the immune system attack cancer cells. The goal is to see …
Matched conditions: CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC